Russo Partners’ Post

Exciting developments in the field of #radiopharmaceutical imaging. Telix Pharmaceuticals has submitted a New Drug Application (NDA) for TLX101-CDx, an investigational PET imaging agent designed to help characterize gliomas, the most common primary brain tumors. This is a significant step forward for patients, as currently, no FDA-approved targeted PET agents are available for imaging brain #cancer. At Ratio, we are encouraged by this news, as we believe that radiopharmaceuticals have the potential to provide patients and clinicians with the information needed to better understand diagnosis and treatment decisions. Read more about this milestone at Targeted Oncology: https://bit.ly/4e3LVej